Receipt of the 59th Annual Okochi Memorial Technology Prize

March 22, 2013
Asahi Kasei Pharma Corp.

Asahi Kasei Pharma received the 59th Annual Okochi Memorial Technology Prize for the development of a genetically-engineered thrombomodulin agent for the treatment of disseminated intravascular coagulation (DIC).

The Okochi Memorial Prizes are a prestigious series of prizes with a rich tradition, awarded to honor outstanding achievements in the field of manufacturing engineering and industrial technology in Japan by the Okochi Memorial Foundation in commemoration of Dr. Masatoshi Okochi. This year’s award ceremony was held today in Tokyo at the Industry Club of Japan.

This Prize was awarded in recognition of the achievements that made possible the practical application of the DIC agent as the world’s first genetically-engineered thrombomodulin (sold as Recomodulin™ in Japan). Most notably, the award recognizes the world’s first genetic cloning of thrombomodulin, the invention of a genetically-engineered thrombomodulin, the establishment of an advanced perfusion culture system, the development of original drug formulation technology, and the establishment and standardization of a methodology for quantifying the pharmacological activity.

Asahi Kasei Pharma will continue to create new value for society through continuous research and development for innovative new drugs.

Recipients of the Prize

Yoshikazu Aoki – General Manager, Development Planning, Clinical Development Center, Asahi Kasei Pharma Corp.

Shuji Yamamoto – former Assistant Director, Technology Planning, Health Care Research and Development Dept., Asahi Kasei Corp.

Hiroki Shigematsu – General Manager, Fuji Pharmaceuticals Plant, Pharmaceuticals Production & Technology Center, Asahi Kasei Pharma Corp.

Goichi Honda – Manager, Scientific Affairs, Pharmaceuticals Sales Division, Asahi Kasei Pharma Corp.

Kazuhisa Tsuruta – Vice President, Asahi Kasei Pharma America Corp.


Adobe Readeris required to view these PDF files.

page top